Shares of Karyopharm Therapeutics Inc. hit a new 52-week low Monday on news that a higher-than-expected rate of sepsis prompted the Newton, Mass.-based firm to reduce the dose in an ongoing phase IIb study testing selinexor in elderly patients with acute myeloid leukemia (AML).